Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Net sales	$ 3,933.9	$ 4,067.4	$ 11,562.5	$ 12,351.0
Biocon Biologics
Disaggregation of Revenue [Line Items]
Net sales		(181.0)		(507.5)
Brands
Disaggregation of Revenue [Line Items]
Net sales	2,533.1	2,540.3	7,398.1	7,577.5
Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	174.4	320.2	449.7	1,065.8
Generics
Disaggregation of Revenue [Line Items]
Net sales	1,226.4	1,206.9	3,714.7	3,707.7
Lipitor
Disaggregation of Revenue [Line Items]
Net sales	381.6	420.4	1,179.5	1,266.1
Norvasc
Disaggregation of Revenue [Line Items]
Net sales	175.5	189.3	560.6	600.1
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	141.7	156.5	423.1	483.9
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	110.5	117.0	336.5	361.9
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	131.9	114.4	355.2	309.7
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	84.7	82.2	255.5	253.4
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	65.5	64.2	194.9	215.4
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	62.7	53.1	173.7	188.7
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	77.5	76.4	224.3	226.5
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	47.9	51.0	145.0	146.7
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	37.7	39.4	115.8	125.3
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	28.2	38.3	119.7	115.5
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	44.1	38.6	155.0	138.0
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	58.3	53.4	160.3	146.1
Influvac ®
Disaggregation of Revenue [Line Items]
Net sales	137.2	159.3	137.5	178.3
Developed Markets | Brands
Disaggregation of Revenue [Line Items]
Net sales	1,391.3	1,327.7	3,923.5	3,931.8
Developed Markets | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	166.1	295.0	428.7	986.1
Developed Markets | Generics
Disaggregation of Revenue [Line Items]
Net sales	851.1	808.8	2,580.5	2,468.8
Greater China | Brands
Disaggregation of Revenue [Line Items]
Net sales	546.5	571.9	1,639.4	1,687.9
Greater China | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	0.0	0.2	0.0	0.5
Greater China | Generics
Disaggregation of Revenue [Line Items]
Net sales	1.9	1.9	5.7	7.0
JANZ | Brands
Disaggregation of Revenue [Line Items]
Net sales	185.7	211.6	583.4	703.7
JANZ | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	8.0	10.9	20.6	33.3
JANZ | Generics
Disaggregation of Revenue [Line Items]
Net sales	140.8	160.5	448.2	496.9
Emerging Markets Segment | Brands
Disaggregation of Revenue [Line Items]
Net sales	409.6	429.1	1,251.8	1,254.1
Emerging Markets Segment | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	0.3	14.1	0.4	45.9
Emerging Markets Segment | Generics
Disaggregation of Revenue [Line Items]
Net sales	232.6	235.7	680.3	735.0
Operating Segment | Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	2,408.5	2,431.5	6,932.7	7,386.7
Operating Segment | Greater China
Disaggregation of Revenue [Line Items]
Net sales	548.4	574.0	1,645.1	1,695.4
Operating Segment | JANZ
Disaggregation of Revenue [Line Items]
Net sales	334.5	383.0	1,052.2	1,233.9
Operating Segment | Emerging Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 642.5	$ 678.9	$ 1,932.5	$ 2,035.0